Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya

View ORCID ProfileStacey Orangi, View ORCID ProfileJohn Ojal, View ORCID ProfileSamuel P. C. Brand, View ORCID ProfileCameline Orlendo, View ORCID ProfileAngela Kairu, View ORCID ProfileRabia Aziza, View ORCID ProfileMorris Ogero, View ORCID ProfileAmbrose Agweyu, View ORCID ProfileGeorge M Warimwe, View ORCID ProfileSophie Uyoga, View ORCID ProfileEdward Otieno, View ORCID ProfileLynette I Ochola-Oyier, View ORCID ProfileCharles N Agoti, Kadondi Kasera, Patrick Amoth, Mercy Mwangangi, Rashid Aman, Wangari Ng’ang’a, View ORCID ProfileIfedayo M O Adetifa, View ORCID ProfileJ Anthony G Scott, View ORCID ProfilePhilip Bejon, View ORCID ProfileMatt. J. Keeling, View ORCID ProfileStefan Flasche, View ORCID ProfileD. James. Nokes, View ORCID ProfileEdwine Barasa
doi: https://doi.org/10.1101/2022.04.21.22274150
Stacey Orangi
1Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
2Institute of Healthcare Management, Strathmore University, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stacey Orangi
  • For correspondence: sorangi@kemri-wellcome.org JOjal@kemri-wellcome.org
John Ojal
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
4The Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John Ojal
  • For correspondence: sorangi@kemri-wellcome.org JOjal@kemri-wellcome.org
Samuel P. C. Brand
5The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK
6School of Life Sciences, University of Warwick, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel P. C. Brand
Cameline Orlendo
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cameline Orlendo
Angela Kairu
1Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angela Kairu
Rabia Aziza
5The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK
6School of Life Sciences, University of Warwick, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rabia Aziza
Morris Ogero
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Morris Ogero
Ambrose Agweyu
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
8Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ambrose Agweyu
George M Warimwe
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
8Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for George M Warimwe
Sophie Uyoga
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie Uyoga
Edward Otieno
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward Otieno
Lynette I Ochola-Oyier
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lynette I Ochola-Oyier
Charles N Agoti
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles N Agoti
Kadondi Kasera
9Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Amoth
9Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercy Mwangangi
9Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rashid Aman
9Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wangari Ng’ang’a
10Presidential Policy & Strategy Unit, The Presidency, Government of Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ifedayo M O Adetifa
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
4The Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ifedayo M O Adetifa
J Anthony G Scott
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
4The Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J Anthony G Scott
Philip Bejon
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
8Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip Bejon
Matt. J. Keeling
5The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK
6School of Life Sciences, University of Warwick, UK
11Mathematics Institute, University of Warwick, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matt. J. Keeling
Stefan Flasche
4The Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan Flasche
D. James. Nokes
3Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
5The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK
6School of Life Sciences, University of Warwick, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. James. Nokes
Edwine Barasa
1Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
2Institute of Healthcare Management, Strathmore University, Nairobi, Kenya
8Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edwine Barasa
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Few studies have assessed the benefits of COVID-19 vaccines in settings where most of the population had been exposed to SARS-CoV-2 infection.

Methods We conducted a cost-effectiveness analysis of COVID-19 vaccine in Kenya from a societal perspective over a 1.5-year time frame. An age-structured transmission model assumed at least 80% of the population to have prior natural immunity when an immune escape variant was introduced. We examine the effect of slow (18 months) or rapid (6 months) vaccine roll-out with vaccine coverage of 30%, 50% or 70% of the adult (> 18 years) population prioritizing roll-out in over 50-year olds (80% uptake in all scenarios). Cost data were obtained from primary analyses. We assumed vaccine procurement at $7 per dose and vaccine delivery costs of $3.90-$6.11 per dose. The cost-effectiveness threshold was USD 919.

Findings Slow roll-out at 30% coverage largely targets over 50-year-olds and resulted in 54% fewer deaths (8,132(7,914 to 8,373)) than no vaccination and was cost-saving (ICER=US$-1,343 (-1,345 to - 1,341) per DALY averted). Increasing coverage to 50% and 70%, further reduced deaths by 12% (810 (757 to 872) and 5% (282 (251 to 317) but was not cost-effective, using Kenya’s cost-effectiveness threshold ($ 919.11). Rapid roll-out with 30% coverage averted 63% more deaths and was more cost-saving (ICER=$-1,607 (-1,609 to -1,604) per DALY averted) compared to slow roll-out at the same coverage level, but 50% and 70% coverage scenarios were not cost-effective.

Interpretation With prior exposure partially protecting much of the Kenyan population, vaccination of young adults may no longer be cost-effective.

What is already known?

  • The COVID-19 pandemic has led to a substantial number of cases and deaths in low-and middle-income countries.

  • COVID-19 vaccines are considered the main strategy of curtailing the pandemic. However, many African nations are still at the early phase of vaccination.

  • Evidence on the cost-effectiveness of COVID-19 vaccines are useful in estimating value for money and illustrate opportunity costs. However, there is a need to balance these economic outcomes against the potential impact of vaccination.

What are the new findings?

  • In Kenya, a targeted vaccination strategy that prioritizes those of an older age and is deployed at a rapid rollout speed achieves greater marginal health impacts and is better value for money.

  • Given the existing high-level population protection to COVID-19 due to prior exposure, vaccination of younger adults is less cost-effective in Kenya.

What do the new findings imply?

  • Rapid deployment of vaccines during a pandemic averts more cases, hospitalisations, and deaths and is more cost-effective.

  • Against a context of constrained fiscal space for health, it is likely more prudent for Kenya to target those at severe risk of disease and possibly other vulnerable populations rather than to the whole population.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by funding from the Bill and Melinda Gates Foundation funded International Decision Support Initiative (IDSI), and funding from the National Institute for Health Research (NIHR) Global Health Research Unit on the Application of Genomics and Modelling to the Control of Virus Pathogens (17/63/82), on Mucosal Pathogens (16/136/46), and on Tackling Infections to Benefit Africa (16/136/33),using UK aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985/Z/20/Z).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All code and data for the transmission model and economic evaluation analysis underlying this study is accessible at the Github repository: https://github.com/SamuelBrand1/KenyaCoVaccines.

https://github.com/SamuelBrand1/KenyaCoVaccines

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 22, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
Stacey Orangi, John Ojal, Samuel P. C. Brand, Cameline Orlendo, Angela Kairu, Rabia Aziza, Morris Ogero, Ambrose Agweyu, George M Warimwe, Sophie Uyoga, Edward Otieno, Lynette I Ochola-Oyier, Charles N Agoti, Kadondi Kasera, Patrick Amoth, Mercy Mwangangi, Rashid Aman, Wangari Ng’ang’a, Ifedayo M O Adetifa, J Anthony G Scott, Philip Bejon, Matt. J. Keeling, Stefan Flasche, D. James. Nokes, Edwine Barasa
medRxiv 2022.04.21.22274150; doi: https://doi.org/10.1101/2022.04.21.22274150
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
Stacey Orangi, John Ojal, Samuel P. C. Brand, Cameline Orlendo, Angela Kairu, Rabia Aziza, Morris Ogero, Ambrose Agweyu, George M Warimwe, Sophie Uyoga, Edward Otieno, Lynette I Ochola-Oyier, Charles N Agoti, Kadondi Kasera, Patrick Amoth, Mercy Mwangangi, Rashid Aman, Wangari Ng’ang’a, Ifedayo M O Adetifa, J Anthony G Scott, Philip Bejon, Matt. J. Keeling, Stefan Flasche, D. James. Nokes, Edwine Barasa
medRxiv 2022.04.21.22274150; doi: https://doi.org/10.1101/2022.04.21.22274150

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1644)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)